General – Cogent Biosciences, Inc.

Skip to main navigation

About
Bezuclastinib
Careers
Pipeline & Publications
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipeline & Publications
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipeline & Publications
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipeline & Publications
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

code

General

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Read more about Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

Read more about Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Read more about Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Read more about Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Read more about Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Read more about Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Read more about Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Read more about Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

Read more about Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

Read more about Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

Pagination

Page 1
Next page

Subscribe to General

Massachusetts Office:
180 Third Avenue, 4th floor
Waltham, MA 02451

Boulder Office:
4840 Pearl E Circle, Suite 100
Boulder, CO 80301

Massachusetts Office:
180 Third Avenue, 4th floor
Waltham, MA 02451

Boulder Office:
4840 Pearl E Circle, Suite 100
Boulder, CO 80301

About
Bezuclastinib
Careers
Pipeline & Publications
Patients & Families
Investors & Media
Legal
Privacy Policy
Cookie Notice
Contact Us

Scroll to Top